Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Seth L. Harrison - aVenture Research

Seth L. Harrison

AddedMar 31, 2024

UpdatedOct 12, 2026

Seth L. Harrison

Seth L. Harrison

Co-Founder, Apple Tree Partners

Seth L. Harrison's Career

Stoke Therapeutics

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Public

$235.1M

Bedford, MA, US

Board Member· Board

Nereid Therapeutics

Series A$50MBoston, MA, US

Board Member· Board

Aethon Therapeutics

Series A$30MNew York City, NY, US

Board Member· Board

Apple Tree Partners

Investment FirmNew York City, NY, US

Co-Founder

Nine Square Therapeutics

Series A$54.5MNew York City, NY, US

Board Member· Board

Elstar Therapeutics

Series A$39MCambridge, MA, US

Board Member· Board

Cure Forward

Series A$27.8MBoston, MA, US

Board Member· Board

Braeburn

Series B$133MPlymouth Meeting, PA, US

Board Member· Board

People Similar to Seth L. Harrison

Greg CosmaBoard Member · Aarvik Therapeutics

Austin GurneyBoard Member · Immune-Onc Therapeutics

Aaron KantoffBoard Member · Stoke Therapeutics

Dave ChennFounder & CEO · Oceanpine Capital

Jakob LovenBoard Member · Arrakis Therapeutics

Roy F. WaldronBoard Member · Starton Therapeutics

Vicky RichonBoard Member · Auron Therapeutics

Leadership at Stoke Therapeutics

Garry E. MenzelBoard Member

Isabel AznarezCo-Founder

Jennifer BursteinBoard Member

Adrian KrainerCo-Founder

Arthur A LevinBoard Member

Edward KayeBoard Member

Similar to Stoke Therapeutics

Stealth BioTherapeuticsNeedham, MA, USTherapiesest. 2007Stealth BioTherapeuticsNeedham, MA, US · est. 2007

US-based Stealth BioTherapeutics develops therapies for genetic mitochondrial and age-related diseases.

Public · $191.4M52

Leadership at Nereid Therapeutics

Robert HuginBoard Member

Michael KauffmanCEO

Similar to Nereid Therapeutics

Faze MedicinesCambridge, MA, USTherapeuticsest. 2020Faze MedicinesCambridge, MA, US · est. 2020

Faze Medicines: A pioneering biotech company specializing in biomolecular condensate therapeutics.

Series A · $81M40

Transition BioCambridge, MA, USDrug Discoveryest. 2020Transition BioCambridge, MA, US · est. 2020

Transition Bio: Pioneering biomolecular condensate analysis tech for precise drug discovery.

Series A · $50M50

Dewpoint TherapeuticsBoston, MA, USDrug Platformest. 2018Dewpoint TherapeuticsBoston, MA, US · est. 2018

Dewpoint Therapeutics: A global biotech firm developing a drug platform targeting biomolecular condensates.

Series C · $287M161

Nerio TherapeuticsLos Angeles, CA, USBiotechest. 2019Nerio TherapeuticsLos Angeles, CA, US · est. 2019

Los Angeles-based biotech company specializing in life sciences. Founded in 2019.

Series A · $6.5M6

Similar to Aethon Therapeutics

Ernexa TherapeuticsCambridge, MA, USCell Therapiesest. 1984Ernexa TherapeuticsCambridge, MA, US · est. 1984

Eterna Therapeutics: Pioneering cell engineering for cancer and immunologic disease treatment.

Public · $49.1M11

Duet BioTherapeuticsPasadena, CA, USCancer Treatments, Immunotherapiesest. 2019Duet BioTherapeuticsPasadena, CA, US · est. 2019

Scopus BioPharma: Innovating targeted immunotherapies for treatment-resistant cancers.

Public · $200k8

Parthenon TherapeuticsCambridge, MA, USCancer Therapiesest. 2019Parthenon TherapeuticsCambridge, MA, US · est. 2019

Parthenon Therapeutics develops innovative anti-cancer therapies, reprogramming the tumor microenvironment.

Series A · $65M43

Asher BioSouth San Francisco, CA, USCancer Treatment, Immunotherapyest. 2019Asher BioSouth San Francisco, CA, US · est. 2019

Asher Bio crafts targeted immunotherapies for cancer and diseases, focusing on precision and innovation.

Series C · $218.2M56

Leadership at Apple Tree Partners

Mark PruzanskiCo-Founder

Similar to Apple Tree Partners

ATPAustin, TX, USest. 2014ATPAustin, TX, US · est. 2014

ATP-I: A technology venture fund enabling rapid growth and sustainable success for emerging tech firms.

Investment Firm9

Atherton Venture PartnersMenlo Park, CA, USest. 2010Atherton Venture PartnersMenlo Park, CA, US · est. 2010

Atherton Venture Partners: A US-based venture capital firm investing in healthcare, life science, and IT sectors.

Investment Firm5

Almond Tree Capital FundDavis, CA, USest. 2013Almond Tree Capital FundDavis, CA, US · est. 2013

Almond Tree Capital LLC: A venture capital firm investing in health tech startups.

Investment Firm50

Olive Tree CapitalBoston, MA, USest. 2016Olive Tree CapitalBoston, MA, US · est. 2016

OT Management, LLC: A specialized investment advisory firm focusing on diverse asset classes.

Investment Firm5

Leadership at Nine Square Therapeutics

Steven AltschulerFounder

Similar to Nine Square Therapeutics

NeuroX1Austin, TX, USDrug Discoveryest. 2021NeuroX1Austin, TX, US · est. 2021

NeuroX1: A computational startup designing novel compounds for neurodegenerative diseases using our proprietary platform.

Libra TherapeuticsSan Diego, CA, USTherapeuticsest. 2019Libra TherapeuticsSan Diego, CA, US · est. 2019

Libra Therapeutics develops novel therapeutics to restore cellular balance in neurodegenerative diseases.

Series A · $29M7

TorMagnus PharmaceuticalsSan Francisco, CA, USDrug Discoveryest. 2022TorMagnus PharmaceuticalsSan Francisco, CA, US · est. 2022

TorMagnus Pharmaceuticals: Using AI to discover novel Parkinson's disease treatments.

Pre-Seed · $500k6

Chaperone TherapeuticsDurham, NC, USDrugs, Therapeuticsest. 2009Chaperone TherapeuticsDurham, NC, US · est. 2009

Chaperone Therapeutics develops innovative therapies for neurodegenerative and rare diseases caused by protein misfolding.

Seed · $456.6k30

Leadership at Elstar Therapeutics

Rupert VesseyBoard Member

Sam HallBoard Member

Steve ArkinstallCEO

Similar to Elstar Therapeutics

Stingray TherapeuticsHouston, TX, USCancer Treatmentsest. 2018Stingray TherapeuticsHouston, TX, US · est. 2018

Stingray Therapeutics: A Houston-based biotech firm innovating cancer immunotherapies since 2018.

Series A · $6.6M6

Elicio TherapeuticsCambridge, MA, USPharmaceuticalsest. 2011Elicio TherapeuticsCambridge, MA, US · est. 2011

Elicio: A pharmaceutical research firm dedicated to re-engineering immune responses to cancer.

Public · $222.3M38

Partner TherapeuticsLexington, MA, USCancer Treatmentsest. 2017Partner TherapeuticsLexington, MA, US · est. 2017

Partner Therapeutics, Inc.: A Massachusetts-based biopharmaceutical company innovating cancer treatments.

Public · $60M227

Starton TherapeuticsParamus, NJ, USCancer Therapiesest. 2017Starton TherapeuticsParamus, NJ, US · est. 2017

Starton Therapeutics: A clinical-stage biotech firm innovating cancer care with transdermal technology.

Pre-Seed · $8.5M38

Leadership at Cure Forward

Martin NaleyFounder

Frank IngariCEO

Similar to Cure Forward

Curelab OncologyDedham, MA, USAnti-Cancer Biologicsest. 2000Curelab OncologyDedham, MA, US · est. 2000

CureLab Oncology: A biotech firm innovating anti-cancer therapies.

Oncology HondurasHuntsville, AL, USCancer Treatmentest. 2016Oncology HondurasHuntsville, AL, US · est. 2016

Oncology Honduras: Providing advanced cancer treatments with cutting-edge technologies.

Seed · $1.1M50

Onko SolutionsAustin, TX, USCancer Detection, Cancer Treatmentest. 2014Onko SolutionsAustin, TX, US · est. 2014

Onko Solutions: Innovating accurate cancer detection, prevention, and treatment for underserved communities.

Series A · $2.5M8

Palm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Leadership at Braeburn

Dennis H. LangerBoard Member

Mike DerkaczCEO

Jerry KarabelasBoard Member

Similar to Braeburn

Bridge TherapeuticsBirmingham, AL, USPharmaceuticalsest. 2016Bridge TherapeuticsBirmingham, AL, US · est. 2016

Bridge Therapeutics: A specialty pharma company focused on chronic pain and opioid addiction solutions.

Series A · $4M9

Therabron TherapeuticsRockville, MD, USProprietary Drugsest. 2007Therabron TherapeuticsRockville, MD, US · est. 2007

Therabron Therapeutics Inc.: A biopharmaceutical firm creating proprietary drugs for specific conditions.

Public · $17.9M30

PronirasSeattle, WA, USDrug Development, Therapeuticsest. 2016PronirasSeattle, WA, US · est. 2016

Proniras Corp: A preclinical-stage biotech firm, founded in 2016, specializing in commercial R&D.

Series B · $13.3M8

Tremeau PharmaceuticalsConcord, MA, USPain Therapiesest. 2016Tremeau PharmaceuticalsConcord, MA, US · est. 2016

Massachusetts-based pharmaceutical company specializing in non-opioid pain therapies.

Late Stage Private · $115.2M11

Star TherapeuticsSouth San Francisco, CA, USTherapeuticsest. 2018

Star TherapeuticsSouth San Francisco, CA, US · est. 2018

Star Therapeutics develops innovative therapies for rare diseases, focusing on novel biology and first-in-class antibody therapeutics.

Series C · $190M48

Astria TherapeuticsBoston, MA, USBiopharmaceuticalsest. 2008Astria TherapeuticsBoston, MA, US · est. 2008

Astria Therapeutics, Inc.: A clinical-stage biopharmaceutical company developing treatments for rare diseases and lipid disorders.

Public · $656.4M24

StrykagenReno, NV, USDiagnostics, TherapeuticsStrykagenReno, NV, US

Strykagen: Innovating diagnostic and therapeutic tools for rare muscle diseases.